{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T03:55:13Z","timestamp":1788753313293,"version":"build-2803163510"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Res."],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s44313-026-00154-1","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T14:40:18Z","timestamp":1784558418000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Response-adapted lenalidomide\u2013dexamethasone (LenDex) intensification after CyBorD induction for transplant-eligible multiple myeloma: the PIANO study"],"prefix":"10.1007","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7529-5585","authenticated-orcid":false,"given":"Daisuke","family":"Minakata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Go","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Kako","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Hiroshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuichi","family":"Ota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Handa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Wake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Meguro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensuke","family":"Usuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiro","family":"Tsukada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Nakasone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinobu","family":"Kanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,20]]},"reference":[{"issue":"2","key":"154_CR1","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.bbmt.2006.09.010","volume":"13","author":"J Koreth","year":"2007","unstructured":"Koreth J, Cutler CS, Djulbegovic B, Behl R, Schlossman RL, Munshi NC, et al. High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: A systematic review and meta-analysis of randomized controlled trials. Biol Blood Marrow Transplant. 2007;13(2):183\u201396. https:\/\/doi.org\/10.1016\/j.bbmt.2006.09.010.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"154_CR2","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1001\/jamaoncol.2017.4600","volume":"4","author":"B Dhakal","year":"2018","unstructured":"Dhakal B, Szabo A, Chhabra S, Hamadani M, D\u2019Souza A, Usmani SZ, et al. Autologous transplantation for newly diagnosed multiple myeloma in the era of novel agent induction: a systematic review and meta-analysis. JAMA Oncol. 2018;4(3):343\u201350. https:\/\/doi.org\/10.1001\/jamaoncol.2017.4600.","journal-title":"JAMA Oncol"},{"key":"154_CR3","doi-asserted-by":"publisher","unstructured":"Moreau P, Attal M, Hulin C, Arnulf B, Belhadj K, Benboubker L, B\u00e9n\u00e9 MC, Broijl A, Caillon H, Caillot D, Corre J, Delforge M, Dejoie T, Doyen C, Facon T, Sonntag C, Fontan J, Garderet L, Jie KS, Karlin L, Kuhnowski F, Lambert J, Leleu X, Lenain P, Macro M, Mathiot C, Orsini-Piocelle F, Perrot A, Stoppa AM, van de Donk NW, Wuilleme S, Zweegman S, Kolb B, Touzeau C, Roussel M, Tiab M, Marolleau JP, Meuleman N, Vekemans MC, Westerman M, Klein SK, Levin MD, Fermand JP, Escoffre-Barbe M, Eveillard JR, Garidi R, Ahmadi T, Zhuang S, Chiu C, Pei L, de Boer C, Smith E, Deraedt W, Kampfenkel T, Schecter J, Vermeulen J, Avet-Loiseau H, Sonneveld P. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet. 2019;394(10192):29\u201238. https:\/\/doi.org\/10.1016\/S0140-6736(19)31240-1. Epub 2019 Jun 3. Erratum in: Lancet. 2024;404(10455):e3. https:\/\/doi.org\/10.1016\/S0140-6736(19)31403-5. PMID: 31171419.","DOI":"10.1016\/S0140-6736(19)31240-1"},{"issue":"8","key":"154_CR4","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1182\/blood.2020005288","volume":"136","author":"PM Voorhees","year":"2020","unstructured":"Voorhees PM, Kaufman JL, Laubach J, Sborov DW, Reeves B, Rodriguez C, et al. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood. 2020;136(8):936\u201345. https:\/\/doi.org\/10.1182\/blood.2020005288.","journal-title":"Blood"},{"issue":"4","key":"154_CR5","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1056\/NEJMoa2312054","volume":"390","author":"P Sonneveld","year":"2024","unstructured":"Sonneveld P, Dimopoulos MA, Boccadoro M, Quach H, Ho PJ, Beksac M, et al. Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2024;390(4):301\u201313. https:\/\/doi.org\/10.1056\/NEJMoa2312054.","journal-title":"N Engl J Med"},{"issue":"14","key":"154_CR6","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","volume":"376","author":"M Attal","year":"2017","unstructured":"Attal M, Lauwers-Cances V, Hulin C, Leleu X, Caillot D, Escoffre M, et al. Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma. N Engl J Med. 2017;376(14):1311\u201320. https:\/\/doi.org\/10.1056\/NEJMoa1611750.","journal-title":"N Engl J Med"},{"issue":"2","key":"154_CR7","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1056\/NEJMoa2204925","volume":"387","author":"PG Richardson","year":"2022","unstructured":"Richardson PG, Jacobus SJ, Weller EA, Hassoun H, Lonial S, Raje NS, et al. Triplet therapy, transplantation, and maintenance until progression in myeloma. N Engl J Med. 2022;387(2):132\u201347. https:\/\/doi.org\/10.1056\/NEJMoa2204925.","journal-title":"N Engl J Med"},{"key":"154_CR8","doi-asserted-by":"publisher","unstructured":"Mai EK, Bertsch U, Pozek E, Fenk R, Besemer B, Hanoun C, Schroers R, von Metzler I, H\u00e4nel M, Mann C, Leypoldt LB, Heilmeier B, Huhn S, Vogel SK, Hundemer M, Scheid C, Blau IW, Luntz S, Weinhold N, Tichy D, Holderried TAW, Trautmann-Grill K, Gezer D, Klaiber-Hakimi M, M\u00fcller M, Shumilov E, Knauf W, Michel CS, Geer T, Riesenberg H, Lutz C, Raab MS, Benner A, Hoffmann M, Weisel KC, Salwender HJ, Goldschmidt H; German-Speaking Myeloma Multicenter Group (GMMG) HD7 Investigators; German-speaking Myeloma Multicenter Group (GMMG) HD7. Isatuximab, lenalidomide, bortezomib, and dexamethasone induction therapy for transplant-eligible newly diagnosed multiple myeloma: final part 1 analysis of the GMMG-HD7 Trial. J Clin Oncol. 2024:JCO2402266. https:\/\/doi.org\/10.1200\/JCO-24-02266.","DOI":"10.1200\/JCO-24-02266"},{"issue":"1","key":"154_CR9","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/s41408-024-01047-1","volume":"14","author":"JN N\u00f8rgaard","year":"2024","unstructured":"N\u00f8rgaard JN, Moore KLF, Sl\u00f8rdahl TS, Vik A, Tvedt THA, Schjesvold F. VRD versus VCD as induction therapy before autologous stem cell transplantation in multiple myeloma: a nationwide population-based study. Blood Cancer J. 2024;14(1):60. https:\/\/doi.org\/10.1038\/s41408-024-01047-1.","journal-title":"Blood Cancer J"},{"issue":"6","key":"154_CR10","doi-asserted-by":"publisher","first-page":"307.e1","DOI":"10.1016\/j.jtct.2022.03.020","volume":"28","author":"A Afrough","year":"2022","unstructured":"Afrough A, Pasvolsky O, Ma J, Srour S, Bashir Q, Saini N, et al. Impact of induction with VCD versus VRD on the outcome of patients with multiple myeloma after an autologous hematopoietic stem cell transplantation. Transplant Cell Ther. 2022;28(6):307.e1-307.e8. https:\/\/doi.org\/10.1016\/j.jtct.2022.03.020.","journal-title":"Transplant Cell Ther"},{"issue":"2","key":"154_CR11","doi-asserted-by":"publisher","first-page":"83.e1","DOI":"10.1016\/j.jtct.2021.10.022","volume":"28","author":"S Sidana","year":"2022","unstructured":"Sidana S, Kumar S, Fraser R, Estrada-Merly N, Giralt S, Agrawal V, et al. Impact of induction therapy with VRD versus VCD on outcomes in patients with multiple myeloma in partial response or better undergoing upfront autologous stem cell transplantation. Transplant Cell Ther. 2022;28(2):83.e1-83.e9. https:\/\/doi.org\/10.1016\/j.jtct.2021.10.022.","journal-title":"Transplant Cell Ther"},{"issue":"30","key":"154_CR12","doi-asserted-by":"publisher","first-page":"4621","DOI":"10.1200\/JCO.2009.27.9158","volume":"28","author":"JL Harousseau","year":"2010","unstructured":"Harousseau JL, Attal M, Avet-Loiseau H, Marit G, Caillot D, Mohty M, et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. J Clin Oncol. 2010;28(30):4621\u20139. https:\/\/doi.org\/10.1200\/JCO.2009.27.9158.","journal-title":"J Clin Oncol"},{"issue":"7","key":"154_CR13","doi-asserted-by":"publisher","first-page":"964","DOI":"10.3324\/haematol.2015.124347","volume":"100","author":"M Merz","year":"2015","unstructured":"Merz M, Salwender H, Haenel M, Mai EK, Bertsch U, Kunz C, et al. Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial. Haematologica. 2015;100(7):964\u20139. https:\/\/doi.org\/10.3324\/haematol.2015.124347.","journal-title":"Haematologica"},{"key":"154_CR14","doi-asserted-by":"publisher","unstructured":"Sonneveld P, Schmidt-Wolf IG, van der Holt B, El Jarari L, Bertsch U, Salwender H, Zweegman S, Vellenga E, Broyl A, Blau IW, Weisel KC, Wittebol S, Bos GM, Stevens-Kroef M, Scheid C, Pfreundschuh M, Hose D, Jauch A, van der Velde H, Raymakers R, Schaafsma MR, Kersten MJ, van Marwijk-Kooy M, Duehrsen U, Lindemann W, Wijermans PW, Lokhorst HM, Goldschmidt HM. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65\/ GMMG-HD4 trial. J Clin Oncol. 2012;30(24):2946\u20122955. https:\/\/doi.org\/10.1200\/JCO.2011.39.6820. Epub 2012 Jul 16. Erratum in: J Clin Oncol. 2012;30(29):3654.","DOI":"10.1200\/JCO.2011.39.6820"},{"key":"154_CR15","doi-asserted-by":"publisher","unstructured":"Jackson GH, Davies FE, Pawlyn C, Cairns DA, Striha A, Collett C, Waterhouse A, Jones JR, Kishore B, Garg M, Williams CD, Karunanithi K, Lindsay J, Wilson JN, Jenner MW, Cook G, Kaiser MF, Drayson MT, Owen RG, Russell NH, Gregory WM, Morgan GJ; UK NCRI Haematological Oncology Clinical Studies Group. Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. Lancet Haematol. 2019;6(12):e616\u2012e629. https:\/\/doi.org\/10.1016\/S2352-3026(19)30167-X.","DOI":"10.1016\/S2352-3026(19)30167-X"},{"issue":"1","key":"154_CR16","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1002\/hon.2452","volume":"36","author":"H Nakasone","year":"2018","unstructured":"Nakasone H, Terasako-Saito K, Hirano T, Wake A, Shimizu S, Kurita N, et al. Targeting complete response with upfront bortezomib consolidation versus observation after the achievement of complete response following autologous transplantation for multiple myeloma (TUBA study). Hematol Oncol. 2018;36(1):202\u20139. https:\/\/doi.org\/10.1002\/hon.2452.","journal-title":"Hematol Oncol"},{"issue":"12","key":"154_CR17","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538\u201348. https:\/\/doi.org\/10.1016\/S1470-2045(14)70442-5.","journal-title":"Lancet Oncol"},{"issue":"8","key":"154_CR18","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328\u201346. https:\/\/doi.org\/10.1016\/S1470-2045(16)30206-6.","journal-title":"Lancet Oncol"},{"issue":"3","key":"154_CR19","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1751-0473-3-17","volume":"16","author":"Z Bursac","year":"2008","unstructured":"Bursac Z, Gauss CH, Williams DK, Hosmer DW. Purposeful selection of variables in logistic regression. Source Code Biol Med. 2008;16(3):17. https:\/\/doi.org\/10.1186\/1751-0473-3-17.","journal-title":"Source Code Biol Med"},{"issue":"3","key":"154_CR20","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Transplant. 2013;48(3):452\u20138. https:\/\/doi.org\/10.1038\/bmt.2012.244.","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"154_CR21","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1038\/bmt.2010.118","volume":"46","author":"IN Micallef","year":"2011","unstructured":"Micallef IN, Ho AD, Klein LM, Marulkar S, Gandhi PJ, Calandra G, et al. Plerixafor (Mozobil) for stem cell mobilization in patients with multiple myeloma previously treated with lenalidomide. Bone Marrow Transplant. 2011;46(3):350\u20135. https:\/\/doi.org\/10.1038\/bmt.2010.118.","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"154_CR22","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/bmt.2013.175","volume":"49","author":"SK Kumar","year":"2014","unstructured":"Kumar SK, Mikhael J, Laplant B, Lacy MQ, Buadi FK, Dingli D, et al. Phase 2 trial of intravenously administered plerixafor for stem cell mobilization in patients with multiple myeloma following lenalidomide-based initial therapy. Bone Marrow Transplant. 2014;49(2):201\u20135. https:\/\/doi.org\/10.1038\/bmt.2013.175.","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"154_CR23","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/S1470-2045(13)70609-0","volume":"15","author":"A Palumbo","year":"2014","unstructured":"Palumbo A, Bringhen S, Kumar SK, Lupparelli G, Usmani S, Waage A, et al. Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. Lancet Oncol. 2014;15(3):333\u201342. https:\/\/doi.org\/10.1016\/S1470-2045(13)70609-0.","journal-title":"Lancet Oncol"},{"issue":"12","key":"154_CR24","doi-asserted-by":"publisher","first-page":"e506","DOI":"10.1038\/bcj.2016.114","volume":"6","author":"JR Jones","year":"2016","unstructured":"Jones JR, Cairns DA, Gregory WM, Collett C, Pawlyn C, Sigsworth R, et al. Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial. Blood Cancer J. 2016;6(12):e506. https:\/\/doi.org\/10.1038\/bcj.2016.114.","journal-title":"Blood Cancer J"},{"issue":"3","key":"154_CR25","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/ajh.27582","volume":"100","author":"I Ntanasis-Stathopoulos","year":"2025","unstructured":"Ntanasis-Stathopoulos I, Filippatos C, Ntanasis-Stathopoulos A, Malandrakis P, Kastritis E, Tsitsilonis OE, et al. Evaluating minimal residual disease negativity as a surrogate endpoint for treatment efficacy in multiple myeloma: a meta-analysis of randomized controlled trials. Am J Hematol. 2025;100(3):427\u201338. https:\/\/doi.org\/10.1002\/ajh.27582.","journal-title":"Am J Hematol"},{"issue":"23","key":"154_CR26","doi-asserted-by":"publisher","first-page":"5988","DOI":"10.1182\/bloodadvances.2020002827","volume":"4","author":"NC Munshi","year":"2020","unstructured":"Munshi NC, Avet-Loiseau H, Anderson KC, Neri P, Paiva B, Samur M, et al. A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma. Blood Adv. 2020;4(23):5988\u201399. https:\/\/doi.org\/10.1182\/bloodadvances.2020002827.","journal-title":"Blood Adv"}],"container-title":["Blood Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44313-026-00154-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s44313-026-00154-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44313-026-00154-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T14:40:19Z","timestamp":1784558419000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s44313-026-00154-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,20]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["154"],"URL":"https:\/\/doi.org\/10.1007\/s44313-026-00154-1","relation":{},"ISSN":["2287-979X","2288-0011"],"issn-type":[{"value":"2287-979X","type":"print"},{"value":"2288-0011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,20]]},"assertion":[{"value":"11 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was initially approved by the Institutional Review Board of Toranomon Hospital (approval date: March 11, 2014), and subsequently reviewed and approved as a specified clinical trial by the Certified Review Board of Jichi Medical University Saitama Medical Center (approval number: jRCTs031180335; approval date: February 25, 2019). Written informed consent was obtained from all participants before enrollment.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Funding statement: This study was supported by funding from Bristol Myers Squibb.Conflict of interest disclosure: S.K., N.T., D.M., and H.N. have received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Janssen Pharmaceutical and Bristol Myers Squibb (BMS); S.K. and H.N. have also received such payments from Sanofi. K.U. has received research grants or contracts from BMS, Ono, Sanofi, and Takeda, and payment or honoraria from BMS, Ono, Pfizer, Sanofi, and Takeda. All other authors declare no conflicts of interest.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"37"}}